ERBB2 and breast carcinoma: Most common adverse reactions (of all grades, with an incidence of ≥30%) of everolimus in patients with HR‐positive/HER2‐negative advanced breast cancer include stomatitis, infection, skin rash, fatigue, diarrhea, and loss of appetite.